Illumina, Inc. (ILMN)
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. The company has a collaboration with Labcorp Holdings Inc. for the development of oncology treatments through applications of sequencing solutions across the healthcare ecosystem; and strategic collaboration with Integrated DNA Technologies to enable a DRAGEN, secondary analysis pipeline for IDT xGena, FFPE and cfDNA next generation sequencing (NGS) library preparation with custom panels, delivering an integrated, end-to-end solution for somatic oncology research. It also has a data partnership with Center for Data-Driven Discovery in Biomedicine to advance research in pediatric cancer and rare disease. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.
- Ticker
- ILMN
- Exchange
- Nasdaq
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Market cap
- $32.18B
- 52-week range
- $112.65 - $309.35
Valuation
- Share price
- $213.13 (close of Nov 6, 2026)
- P/E (TTM)
- 36.25x
- Price to book
- 10.23x
- Price to free cash flow
- 30.45x
- Enterprise value
- $33.16B
- Book value per share
- $20.83
Price performance
| Period | Change |
|---|---|
| 1 day | +2.47% |
| 5 days | -9.69% |
| 1 month | -22.08% |
| 3 months | +10.02% |
| 6 months | +49.48% |
| Year to date | +62.50% |
| 1 year | +75.98% |
| 3 years | +94.16% |
| 5 years | -46.32% |
| 10 years | +62.74% |
| All time | +1,018.65% |
Short interest
- As of
- Oct 15, 2026
- Short % of float
- 8.45%
- Shares short
- 7.89M
- Days to cover
- 2.94
- Change since prior report
- -16.75%
- Source
- FINRA consolidated short interest
Members of Congress who disclosed ILMN trades
Lisa McClain · Thomas Kean · Gilbert Ray Cisneros
Super investors holding ILMN
Samantha McLemore (Patient Capital Management, LLC) · Ray Dalio (Bridgewater Associates)
Profitability and growth
- Return on equity
- 31.22%
- Return on invested capital
- 10.82%
- Return on assets
- 12.79%
- Return on capital employed
- 15.95%
- Gross margin
- 66.08%
- Net margin
- 19.57%
- EBITDA margin
- 24.80%
- Revenue growth
- -0.66%
- Free cash flow growth
- 31.31%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 3.28%
- Current ratio
- 2.63x
- Net debt to EBITDA
- 0.71x
Latest reported year
- Period end
- Dec 28, 2025
- Fiscal year
- 2025
- Revenue
- $4.34B
- Cost of revenue
- $1.47B
- Gross profit
- $2.87B
- EBITDA
- $1.08B
- Net income
- $850.00M
- Earnings per share
- $5.47
- Research and development
- $967.00M
- Interest expense
- $101.00M
- Shares outstanding
- 155.00M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|---|---|---|---|
| 2025-12-28 | $4.34B | $2.87B | $850.00M | $5.47 |
| 2024-12-29 | $4.37B | $2.86B | -$1.22B | -$7.69 |
| 2023-12-31 | $4.50B | $2.74B | -$1.16B | -$7.34 |
| 2023-01-01 | $4.58B | $2.97B | -$4.40B | -$28.00 |
| 2022-01-02 | $4.53B | $3.15B | $762.00M | $5.07 |
| 2021-01-03 | $3.24B | $2.20B | $656.00M | $4.48 |
| 2019-12-29 | $3.54B | $2.47B | $1.00B | $6.81 |
| 2018-12-30 | $3.33B | $2.30B | $826.00M | $5.63 |
| 2017-12-31 | $2.75B | $1.83B | $726.00M | $4.96 |
| 2017-01-01 | $2.40B | $1.67B | $463.00M | $3.09 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|---|---|---|---|
| 2025-12-28 | 66.08% | 19.57% | 31.22% | 10.82% |
| 2024-12-29 | 65.44% | -27.97% | -51.54% | -16.68% |
| 2023-12-31 | 60.92% | -25.78% | -20.21% | -13.35% |
| 2023-01-01 | 64.83% | -96.07% | -66.74% | -41.16% |
| 2022-01-02 | 69.69% | 16.84% | 7.09% | -1.00% |
| 2021-01-03 | 68.01% | 20.25% | 13.98% | 5.76% |
| 2019-12-29 | 69.63% | 28.28% | 21.72% | 13.20% |
| 2018-12-30 | 69.01% | 24.78% | 21.48% | 11.28% |
| 2017-12-31 | 66.35% | 26.38% | 26.41% | 7.47% |
| 2017-01-01 | 69.47% | 19.31% | 20.40% | 13.61% |
Cash and debt by year
| Period end | Cash | Debt |
|---|---|---|
| 2025-12-28 | $1.63B | - |
| 2024-12-29 | $1.22B | - |
| 2023-12-31 | $1.05B | - |
| 2023-01-01 | $2.04B | - |
| 2022-01-02 | $1.34B | $702.00M |
| 2021-01-03 | $3.47B | $673.00M |
| 2019-12-29 | $3.41B | $1.14B |
| 2018-12-30 | $3.51B | $890.00M |
| 2017-12-31 | $2.15B | $1.18B |
| 2017-01-01 | $1.56B | $1.06B |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|---|---|
| 2025-12-28 | $931.00M | $275.00M |
| 2024-12-29 | $709.00M | $370.00M |
| 2023-12-31 | $283.00M | $380.00M |
| 2023-01-01 | $106.00M | $366.00M |
| 2022-01-02 | $337.00M | $754.00M |
| 2021-01-03 | $891.00M | $194.00M |
| 2019-12-29 | $842.00M | $194.00M |
| 2018-12-30 | $846.00M | $193.00M |
| 2017-12-31 | $565.00M | $164.00M |
| 2017-01-01 | $519.00M | $129.00M |
Investor relations
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|---|---|
| 2026-10-29 | Sep 2026 | $1.36 |
| 2026-07-30 | Jun 2026 | $1.23 |
| 2026-04-30 | Mar 2026 | $1.05 |
| 2026-02-05 | Dec 2025 | $1.26 |
| 2025-10-30 | Sep 2025 | $1.16 |
| 2025-07-31 | Jun 2025 | $1.02 |
| 2025-05-08 | Mar 2025 | $0.96 |
| 2025-02-06 | Dec 2024 | $0.92 |
Filings and sources
- Company website
- illumina.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Mettler-Toledo International Inc (MTD) · Waters Corp (WAT) · Quest Diagnostics Inc (DGX) · IDEXX Laboratories Inc (IDXX) · Labcorp Holdings Inc. (LH) · IQVIA Holdings Inc. (IQV) · Medpace Holdings, Inc. (MEDP) · Agilent Technologies, Inc. (A)
Understanding these figures
Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades